Tumor cell resistance against targeted therapeutics: the density of cultured glioma tumor cells enhances Stat3 activity and offers protection against the tyrosine kinase inhibitor canertinib
Authors:
Open Access
- 14 October 2016
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in MedChemComm
- Vol. 8 (1) , 96-102
Abstract
Tumor cell resistance to drug treatment severely limits the therapeutic success of treatment.Keywords
This publication has 33 references indexed in Scilit:
- Feedback Activation of STAT3 as a Cancer Drug-Resistance MechanismTrends in Pharmacological Sciences, 2016
- Cell-cell and cell-matrix adhesion in survival and metastasis: Stat3 versus AktBioMolecular Concepts, 2015
- Canertinib induces ototoxicity in three preclinical modelsHearing Research, 2015
- STAT3 the oncogene – still eluding therapy?The FEBS Journal, 2015
- Mechanism-based cancer therapy: resistance to therapy, therapy for resistanceOncogene, 2014
- Resistance of Cancer Cells to Targeted Therapies Through the Activation of Compensating Signaling LoopsCurrent Signal Transduction Therapy, 2014
- JAK2/STAT5 Inhibition Circumvents Resistance to PI3K/mTOR Blockade: A Rationale for Cotargeting These Pathways in Metastatic Breast CancerCancer Cell, 2012
- The R(h)oads to Stat3: Stat3 activation by the Rho GTPasesExperimental Cell Research, 2011
- Activated Rac1 requires gp130 for Stat3 activation, cell proliferation and migrationExperimental Cell Research, 2010
- Characterization of Tu-2449, a glioma cell line derived from a spontaneous tumor in GFAP-v-src-transgenic mice: comparison with established murine glioma cell lines.International Journal of Oncology, 1999